Drugs / Tarafenacin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01458197 | Sep 2011 → Aug 2012 | overactive bladder | Kwang Dong Pharmaceutical co., ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tarafenacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01458197 ↗ |
| Route | Oral | “Administered as Oral Daily Dose” NCT01458197 ↗ |